Writing in three separate international patents (I, II & III), Colgate-Palmolive said it had created different oral care compositions comprising a cannabinoid, in particular CBD, integrated with an orally acceptable carrier. These blends, it send, could be used to make a range of oral care products, including toothpaste, mouthwash, oral gels, chewing gum and mouth spray, among others.
The first blend integrated CBD or other cannabinoids with a thickening system comprised of xanthan gum and carrageenan; the second blend included CBD or other cannabinoids alongside zinc ion sources for additional antimicrobial protection and strengthening; and the third blend mixed CBD or other cannabinoids with amino acids that targeted cavity formation and tooth sensitivity.
Cannabinoid oral care – CBD has ‘antibacterial and anti-inflammatory properties’
Colgate-Palmolive said “unchecked bacterial growth” in the oral cavity could lead to “a number of adverse conditions”, including gingivitis – an inflammation of the gums and one of the most common disorders – as well as abscesses and cold sores which also involved inflammation.
“Accordingly, there is a need for oral care compositions with antibacterial efficacy, but which are also palatable and desirable for the user,” Colgate-Palmolive wrote in its patent filings.
“…Without being bound by theory, it is believed that oral care compositions comprising cannabinoids such as CBD provide antibacterial and anti-inflammatory properties, for example, and are well-suited to treat a variety of oral diseases and disorders,” the company said.